omniture
logo
Search
ACEPODIA
Media Room

Latest News

rss

Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases

* Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as ...

2024-09-04 05:00 1576

Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy

* ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Fact...

2024-02-05 08:00 1475

Acepodia Announces Nobel Laureate Carolyn Bertozzi, Ph.D., as Chief Scientific Advisor

ALAMEDA, Calif. and TAIPEI, Sept. 18, 2023 /PRNewswire/ -- Acepodia, a clinical stage biotechnology...

2023-09-18 19:00 1174

Acepodia Secures $100 Million Series D Financing to Advance

First-In-Class Cell Therapies with Antibody-Cell Conjugation (ACC) Platform Series D led by Digital...

2023-06-06 18:00 1904

Acepodia Announces First Patient Dosed in Phase 1 Clinical Trial of ACE1831, an Anti-CD20 Armed Allogeneic Gamma Delta T-cell Therapy in Development to Treat Patients with Non-Hodgkin's Lymphoma

ALAMEDA, Calif. and TAIPEI, May 22, 2023 /PRNewswire/ -- Acepodia, a clinical stage biotechnology c...

2023-05-23 00:00 2138

Acepodia to Present Preclinical Data of Gamma Delta T cell Therapy Candidate, ACE2016, an off-the-shelf EGFR-targeting γδ2 T cell therapy against EGFR-expressing solid tumors

ALAMEDA, Calif. and TAIPEI, March 27, 2023 /PRNewswire/ -- Acepodia, a clinical-stage biotechnology...

2023-03-28 10:00 1561

Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic gamma delta T-cell Therapy Candidate to Treat Patients with non-Hodgkin's Lymphoma

ACE1831 is a potential antibody‑armed allogeneic gamma delta T cell therapy developed using Acepodi...

2022-06-20 20:00 1938